Zobrazeno 1 - 10
of 14 331
pro vyhledávání: '"Endocrine therapy"'
Publikováno v:
Discover Oncology, Vol 15, Iss 1, Pp 1-10 (2024)
Abstract Objective The objective of this study is to assess the efficacy and safety of combining goserelin with anastrozole in neoadjuvant endocrine therapy (NET) for patients diagnosed with premenopausal breast cancer. Methods A retrospective analys
Externí odkaz:
https://doaj.org/article/ab75bbc867db4da6a0317a2c6433a752
Autor:
Bartomeu Fullana, Serafín Morales, Anna Petit, Ania Alay, Helena Verdaguer, Fina Climent, Valentí Navarro-Perez, Mónica Cejuela, Patricia Galvan, Anna Gumà, Antonio Llombart-Cussac, David Cordero, Oriol Casanovas, Aleix Prat, Miguel Gil-Gil, Sonia Pernas
Publikováno v:
Scientific Reports, Vol 14, Iss 1, Pp 1-8 (2024)
Abstract Neoadjuvant endocrine therapy (NET) for hormone receptor-positive (HR+) breast cancer might be as effective as chemotherapy, with a better toxicity profile. Blocking a crucial process such as angiogenesis with sunitinib may have a synergisti
Externí odkaz:
https://doaj.org/article/73d2bd5e8b3149adab539c333f43a859
Autor:
Guilherme Nader-Marta, Christian Singer, Dominik Hlauschek, Angela DeMichele, Paolo Tarantino, Evandro de Azambuja, Georg Pfeiler, Miguel Martin, Justin M. Balko, Zbigniew Nowecki, Marija Balic, Adam M. Brufsky, Arlene Chan, Patrick G. Morris, Tufia Haddad, Sibylle Loibl, Yuan Liu, Lidija Soelkner, Christian Fesl, Erica L. Mayer, Michael Gnant, on behalf of the PALLAS groups and investigators
Publikováno v:
Breast Cancer Research, Vol 26, Iss 1, Pp 1-10 (2024)
Abstract Background Bidirectional crosstalk between HER2 and estrogen receptor (ER) pathways may influence outcomes and the efficacy of endocrine therapy (ET). Low HER2 expression levels (HER2-low) have emerged as a predictive biomarker in patients w
Externí odkaz:
https://doaj.org/article/c4f4965043a847fba7a786c64cdbe554
Publikováno v:
Current Oncology, Vol 31, Iss 10, Pp 5873-5888 (2024)
(1) Background: While there is extensive documentation on the medical experience of breast cancer, a thorough understanding of the various stages of endocrine therapy remains insufficient. The aim of this study was to map the experiences and coping s
Externí odkaz:
https://doaj.org/article/062d4a42ad9c42948fef7555201297b2
Autor:
Ran Ran, Shidi Zhao, Yan Zhou, Xinyue Hang, Hui Wang, Yuan Fan, Yusi Zhang, Yifan Qiao, Jin Yang, Danfeng Dong
Publikováno v:
BMC Cancer, Vol 24, Iss 1, Pp 1-17 (2024)
Abstract Background Different hormone receptor (HR) expression patterns have significant biological and therapeutic implications in patients with human epidermal growth factor receptor 2 (HER2)-positive breast cancer. However, the distinction between
Externí odkaz:
https://doaj.org/article/c62db2b92ea6485b8eea8eb9f1be7b12
Publikováno v:
Journal of Medical Case Reports, Vol 18, Iss 1, Pp 1-5 (2024)
Abstract Background Breast cancer is the most common cancer in women. Progression-free survival for hormone receptor-positive/human epidermal growth factor receptor-2-negative metastatic breast cancer treated with endocrine therapy in combination wit
Externí odkaz:
https://doaj.org/article/22f8c3121cd24a848570b640a455bd4c
Autor:
Sharon F. McGee, Mark Clemons, Gregory Pond, Jean-Michel Caudrelier, Michelle Liu, Mashari Jemaan Alzahrani, Terry L. Ng, Arif A. Awan, Sandeep Sehdev, John Hilton, Marie-France Savard, Lesley Fallowfield, Vikaash Kumar, Orit Freedman, Lisa Vandermeer, Brian Hutton, Jean-Marc Bourque
Publikováno v:
Current Oncology, Vol 31, Iss 8, Pp 4531-4545 (2024)
Concerns exist regarding increased toxicities, including endocrine therapy toxicity, with concurrent radiation and endocrine therapy in early breast cancer (EBC). We present a pragmatic, randomized trial comparing concurrent versus sequential endocri
Externí odkaz:
https://doaj.org/article/2fd4e23646ed407ea822b33ad3dcffab
Publikováno v:
BMC Cancer, Vol 24, Iss 1, Pp 1-14 (2024)
Abstract Background Does incorporating Cyclin-dependent kinase 4/6 (CDK4/6) inhibitors into endocrine therapy (ET) effectively enhance survival outcomes, notably overall survival (OS), among individuals with hormone receptor-positive (HR+), human epi
Externí odkaz:
https://doaj.org/article/d64949f51d5946d6bc944246b75adc5d
Autor:
Annamaria Salvati, Giorgio Giurato, Jessica Lamberti, Ilaria Terenzi, Laura Crescenzo, Viola Melone, Luigi Palo, Alessandro Giordano, Francesco Sabbatino, Giuseppina Roscigno, Cristina Quintavalle, Gerolama Condorelli, Francesca Rizzo, Roberta Tarallo, Giovanni Nassa, Alessandro Weisz
Publikováno v:
Molecular Cancer, Vol 23, Iss 1, Pp 1-11 (2024)
Abstract Identifying master epigenetic factors controlling proliferation and survival of cancer cells allows to discover new molecular targets exploitable to overcome resistance to current pharmacological regimens. In breast cancer (BC), resistance t
Externí odkaz:
https://doaj.org/article/c02e9b5b03f246858d4207d54d783e59
Autor:
Zhe-Yu Hu, Binliang Liu, Ning Xie, Xiaohong Yang, Liping Liu, Huawu Xiao, Jing Li, Hui Wu, Jianxiang Gao, Jun Lu, Xuming Hu, Min Cao, Zhengrong Shui, Can Tian, Quchang Ouyang
Publikováno v:
BMC Cancer, Vol 24, Iss 1, Pp 1-10 (2024)
Abstract Aims This investigation aims to elucidate the treatment status of advanced HR+/HER2- breast cancer patients in Hunan Province of Central Southern China from November 2021 to December 2022. Methods Data from 301 patients with advanced HR+/HER
Externí odkaz:
https://doaj.org/article/e9c30214395a45e9b2c6da56ab5e2a2c